Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript

PresentationThank you for standing by, and welcome to the AVLAYAH FDA Approval Call. [Operator Instructions] As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Laura Hansen, Vice President of Investor Relations. Please go ahead.Laura Hansen Thank you, Jonathan, and good day, everyone. Thank you for joining us today for our AVLAYAH FDA Approval Conference Call. I'm Laura Hansen, Vice President of Investor Relations at Denali Therapeutics. Joining me ...